Japan's New OTC Law Leads To Sales Decline In Higher-Risk Drugs
This article was originally published in PharmAsia News
Two months into Japan's revised Pharmaceutical Affairs Law, drug makers are seeing a drop in sales for drugs with a higher risk of side effects. Similarly, mail-order companies are experiencing a sharp drop-off in sales of nonprescription drugs because of tighter regulations. The law that became effective June1 loosened regulations governing over-the-counter drugs by allowing stores other than pharmacies to sell them. But the law retained a requirement that pharmacists be on duty to explain possible side effects before drugs classified as Category 1 could be sold. (Click here for more
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.